EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial

Eiji Shimizu, Daisuke Sato, Mirai Miyoshi, Haruna Ebisu, Kohei Takahashi, Yosuke Inaba, Yuichi Inoue, Masumi Osao, Masahiro Takeshima, Masaya Ogasawara, Yoshiyuki Hirano, Hideki Hanaoka

Sleep Medicine · 2026-12 · 148 · 109222

DOI: 10.1016/j.sleep.2026.109222 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Sleep Medicine, 2026-12. Verfasst von Eiji Shimizu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cognitive Behavioral Physiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuouku, Chiba, 260-8670, Japan; Research…. Hauptthemen laut MEDLINE: Zolpidem, Sleep Initiation and Maintenance Disorders, Cognitive Behavioral Therapy, Hypnotics and Sedatives. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the efficacy and safety of a novel, concise 5-week digital cognitive behavioral therapy for insomnia (dCBT-I) application, "IIIP MED: Sleepy Med," compared to zolpidem. METHODS: This exploratory randomized controlled trial enrolled patients with chronic sleep-onset insomnia who remained symptomatic after a 4-week screening period following sleep hygiene education. Participants were randomized to either the fully unguided dCBT-I group or the zolpidem (5 mg/day) group for a 5-week treatment period, followed by a 5-week follow-up. The primary outcome was the change in subjective Sleep Onset Latency (sSOL) from baseline at Week 5. Secondary outcomes included objective sleep parameters via portable electroencephalography (EEG) and safety assessments. RESULTS: At Week 5, the mean sSOL change was -20.65 min (95% CI: [-32.05, -9.65]) in the dCBT-I group (n = 11) and -22.42 min (95% CI: [-29.37, -15.46]) in the zolpidem group (n = 13), with no significant difference between groups (p = 0.7729). At the Week 10 follow-up, the dCBT-I group (n = 9) demonstrated sustained improvement (-29.02 min, 95% CI: [-51.49, -6.54]), whereas the zolpidem group (n = 12) showed a slight recurrence of symptoms (-16.19 min, 95% CI: [-27.08, -5.31], p = 0.2634). The dCBT-I group showed significantly greater improvement in Dysfunctional Beliefs and Attitudes about Sleep at Week 10. No treatment-related adverse events occurred in the dCBT-I group, while one case of daytime somnolence was reported in the zolpidem group. CONCLUSION: The dCBT-I application was associated with an improvement in sSOL over 5 weeks, with no statistically significant between-group difference compared with zolpidem. Furthermore, the improvement in the dCBT-I group was maintained during the 5-week post-treatment follow-up. Given the exploratory design and small sample size (N = 24), the study was underpowered, and these findings should be interpreted with caution. Larger adequately powered confirmatory trials are warranted. TRIAL REGISTRATION: jRCT2032230353.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZolpidemSleep Initiation and Maintenance DisordersCognitive Behavioral TherapyHypnotics and SedativesHumansFemaleMaleTreatment OutcomeMiddle AgedAdultElectroencephalography

Stichwörter der Autor:innen

Cognitive behavioral therapyInternet-based treatmentPsychotherapy outcome researchRandomized controlled trialSleep disorder

Substanzen

ZolpidemHypnotics and Sedatives

Autor:innen und Institutionen

  • Department of Cognitive Behavioral Physiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuouku, Chiba, 260-8670, Japan; Research Center for Child Mental Development, Chiba University, 1-8-1 Inohana,…
  • Research Center for Child Mental Development, Chiba University, 1-8-1 Inohana, Chuouku, Chiba, 260-8670, Japan; Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-…
  • Department of Cognitive Behavioral Physiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuouku, Chiba, 260-8670, Japan. Electronic address: mirai_m@chiba-u.jp.
  • Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuouku, Chiba, 260-8677, Japan. Electronic address: h.ebisu@chiba-u.jp.
  • Biostatistics Section, Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuouku, Chiba, 260-8677, Japan. Electronic address: kohei.high84@chiba-u.jp.
  • Biostatistics Section, Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuouku, Chiba, 260-8677, Japan. Electronic address: y.inaba@chiba-u.jp.

Förderung

  • AMED

Zitieren

APA

Shimizu, E., Sato, D., Miyoshi, M., Ebisu, H., Takahashi, K., Inaba, Y., Inoue, Y., Osao, M., Takeshima, M., Ogasawara, M., Hirano, Y., & Hanaoka, H. (2026). Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial. Sleep Medicine, 148, 109222. https://doi.org/10.1016/j.sleep.2026.109222

Vancouver

Shimizu E, Sato D, Miyoshi M, Ebisu H, Takahashi K, Inaba Y, et al. Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial. Sleep Medicine. 2026;148:109222. doi:10.1016/j.sleep.2026.109222

BibTeX
@article{Shimizu2026,
  author = {Shimizu, Eiji and Sato, Daisuke and Miyoshi, Mirai and Ebisu, Haruna and Takahashi, Kohei and Inaba, Yosuke and Inoue, Yuichi and Osao, Masumi and Takeshima, Masahiro and Ogasawara, Masaya and Hirano, Yoshiyuki and Hanaoka, Hideki},
  title = {Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial},
  journal = {Sleep Medicine},
  year = {2026},
  volume = {148},
  pages = {109222},
  doi = {10.1016/j.sleep.2026.109222}
}
Kostenlos starten →